报告二，https://www.google.com/url?sa=t&source=web&rct=j&url=https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1073704/acute-hepatitis-technical-briefing-2.pdf Part 1. Working hypotheses The following hypotheses are all being actively tested by the investigations in process. There are increased paediatric acute non-A-E hepatitis presentations due to: 1. A normal adenovirus infection, due to one of: a. Abnormal susceptibility or host response which allows adenovirus infection to progress more frequently to hepatitis (whether direct or immunopathological), for example from lack of exposure during the coronavirus (COVID-19) pandemic. b. An exceptionally large wave of normal adenovirus infections, causing a very rare or under-recognised complication to present more frequently. c. Abnormal susceptibility or host response to adenovirus due to priming by a prior infection with SARS-CoV-2 (including Omicron restricted) or another infection. d. Abnormal susceptibility or host response to adenovirus due to a coinfection with SARS-CoV-2 or another infection. e. Abnormal susceptibility or host response to adenovirus due to a toxin, drug or environmental exposure. 2. A novel variant adenovirus, with or without a contribution from a cofactor as listed above. 3. A post-infectious SARS-CoV-2 syndrome (including an Omicron restricted effect). 4. A drug, toxin or environmental exposure. 5. A novel pathogen either acting alone or as a coinfection. 6. A new variant of SARS-CoV-2.
报告二，https://www.google.com/url?sa=t&source=web&rct=j&url=https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1073704/acute-hepatitis-technical-briefing-2.pdf
Part 1. Working hypotheses The following hypotheses are all being actively tested by the investigations in process. There are increased paediatric acute non-A-E hepatitis presentations due to: 1. A normal adenovirus infection, due to one of: a. Abnormal susceptibility or host response which allows adenovirus infection to progress more frequently to hepatitis (whether direct or immunopathological), for example from lack of exposure during the coronavirus (COVID-19) pandemic. b. An exceptionally large wave of normal adenovirus infections, causing a very rare or under-recognised complication to present more frequently. c. Abnormal susceptibility or host response to adenovirus due to priming by a prior infection with SARS-CoV-2 (including Omicron restricted) or another infection. d. Abnormal susceptibility or host response to adenovirus due to a coinfection with SARS-CoV-2 or another infection. e. Abnormal susceptibility or host response to adenovirus due to a toxin, drug or environmental exposure. 2. A novel variant adenovirus, with or without a contribution from a cofactor as listed above. 3. A post-infectious SARS-CoV-2 syndrome (including an Omicron restricted effect). 4. A drug, toxin or environmental exposure. 5. A novel pathogen either acting alone or as a coinfection. 6. A new variant of SARS-CoV-2.